[Measurement and the clinical significance for the intraocular concentrations of carboplatin after systemic and local administration in rabbits].
OBJECTIVE
To investigate and compare the concentrations of carboplatins achieved in the aqueous and vitreous humors after intravenous or subconjunctivaly injection and to investigate whether local administration of carboplatin might result in higher concentrations in the aqueous and vitreous humor.


METHODS
Four New Zealand rabbits were treated with carboplatin (18.7 mg/kg) in intravenous. The other 4 rabbits were injected with carboplatin (10 mg/ml 0.5 ml) in right eyes subconjunctivaly. The Samples of the aqueous and vitreous humors of rabbits were drawed at 1, 2, 3 hours after the end of infusion and measured the concentration of carboplatin with atomic absorption spectroscopy. The agent dose of systemic infusion were 8 fold for that in subconjunctival delivery.


RESULTS
The concentrations of carboplatin in aqueous and vitreous humors treated with intravenous after 1, 2, 3 hours were 140, 330, 180 ng/ml and 20, 40, 17 ng/ml. The concentration of carboplatin in aqueous and vitreous humors treated with subconjunctively after 1, 2, 3 hours were 2,650, 4,390, 2,780 microg/ml and 160, 250, 110 ng/ml. There is statistical significance between the concentrations of carboplatin of aqueous and vitreous humor after intravenous and subconjunctival (P < 0.01).


CONCLUSIONS
The delivery of subconjunctival of carboplatin result in higher concentrations in aqueous and vitreous humors than intravenous administation. The result suggest that local delivery of chemotherapeutic drugs should elevate the intraocular drugs concentration and be effective for retinoblastoma treatment.
Mao
Yuxiang
Y
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.
Wu
Zhongyao
Z
Lin
Shaofen
S
Li
Wei
W
D000287:Administration, Topical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001082:Aqueous Humor / Q000378:metabolism*; D016190:Carboplatin / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous; D011817:Rabbits; D019572:Retinal Neoplasms / Q000188:drug therapy; D012175:Retinoblastoma / Q000188:drug therapy; D014018:Tissue Distribution; D014822:Vitreous Body / Q000378:metabolism*
D000970:Antineoplastic Agents; D016190:Carboplatin